Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Cuff
Brandon Cuff, Claremont, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20120066699 | DYNAMIC NATIVE BINDING FOR MANAGED ASSEMBLIES - A method, apparatus, system, article of manufacture, and computer readable storage medium provides the ability to dynamically bind a native assembly from a managed assembly. A managed assembly (e.g., a dynamically linked library (DLL)) is obtained. In the managed assembly, native application program interface entry points are identified. For each of the entry points, intended platform(s) and associated correct native assembly(ies) are specified in the managed assembly. The managed assembly is deployed onto a computer. For example, the single collection of managed and native assemblies can be deployed to all targeted computers, which consist of varying platform environments. During runtime execution, the executing platform of the application is determined. Based on the executing platform, an intended platform is selected and the entry points are bound to the correct native assembly. | 03-15-2012 |
Carolyn A. Cuff, Grafton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090311253 | Dual Variable Domain Immunoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 12-17-2009 |
| 20110165066 | INTERLEUKIN-13 BINDING PROTEINS - The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental. | 07-07-2011 |
Christopher Cuff, Kelso Queensland AU
| Patent application number | Description | Published |
|---|---|---|
| 20090214408 | PREPARATION AND USE OF CATIONIC HALIDES, SEQUESTRATION OF CARBON DIOXIDE - A process is described for sequestering carbon dioxide. In the process, a carbonate, oxide or hydroxide of a divalent cation is reacted with the carbon dioxide and water and/or with a species resulting from the dissolution of the carbon dioxide in water, to form a hydrogen carbonate of the divalent cation. The carbonate, oxide or hydroxide of the divalent cation has a low solubility in water. The divalent cation of the hydrogen carbonate of the divalent cation thus formed is exchanged for a monovalent cation using an ion exchange medium, to produce a solution of a hydrogen carbonate of the monovalent cation. | 08-27-2009 |
David P. Cuff, Oshkosh, WI US
| Patent application number | Description | Published |
|---|---|---|
| 20120098172 | GAS SPRING CONTROL SYSTEM AND METHOD - A vehicle suspension system includes a pump, a gas spring, and an accumulator. The suspension system also includes a controller for adjusting the suspension system. The controller has a processing circuit configured to receive a measure of gas in the spring. The processing circuit is further configured to calculate a difference between a target value and a current value based on the received measure of gas. The processing circuit is also configured to provide an output for adjusting the gas in the spring in response to the calculated difference. | 04-26-2012 |
Lisa M. Cuff, Leominster, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110184021 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors - A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. | 07-28-2011 |